Evidence at scale, breakthroughs at speed

Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)

This study used advanced machine learning methods to identify a cohort of over 195,000 patients with EBC from the Flatiron Health Panoramic database and found that a positive ctDNA test is a strong indicator of higher recurrence risk and worse OS across all breast cancer subtypes.

Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): insights by PTEN status

This study used the Flatiron Health-Foundation Medicine mPC Clinico-Genomic Database to examine over 1,600 men diagnosed with mHSPC and provides important real-world evidence that PTEN alterations are associated with worse overall survival in patients with mHSPC.

Impact of social determinants of health (SDOH) on mortality in diffuse large b-cell lymphoma (DLBCL) using real-world data

Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at Anschutz

This study used real-world data from over 6,800 adults with DLBCL to examine how SDOH—like economic status, healthcare access, neighborhood resources, and racial segregation—impact survival.

Real-world surgical and treatment patterns after neoadjuvant checkpoint inhibition in US patients with stage II/III non-small cell lung cancer

Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of Chicago

This study used real-world data to examine how often patients with stage II or III NSCLC undergo surgery after receiving a combination of immunotherapy and chemotherapy and the reasons patients did not proceed to surgery.

Molecular residual disease (MRD) in solid tumors

Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer Center

This research described a multicenter, prospective, observational biospecimen collection study, activated within a technology-enabled network of sites, demonstrating how technology and pragmatic study design can make cancer research more efficient, inclusive, and relevant to real-world patients.

Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States

This research used real-world data to examine how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer, highlighting that not all patients are benefiting.

Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study

Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood Specialists

This study evaluated the performance of an electronic health record-based centralized trial screening service in a prospective multiple myeloma study, focusing on accrual of historically underrepresented racial and ethnic populations.

A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC)

Partner: Incyte

This study used the Flatiron Health Panoramic database comprised of >280K patients with NSCLC, to identify a cohort of 13,000 eligible patients with mNSCLC and investigate treatment patterns and factors associated with selection of a PD-(L)1 inhibitor as first-line treatment.

A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens

Partners: Merck & Co, MSD UK, Mayo Clinic

This research used real-world data to highlight a major unmet need for better treatment options for chronic lymphocytic leukemia patients who have already received both cBTKi and BCL2i, especially for patients with relapsed/refractory disease.

Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting

Partners: Cleveland Clinic, Merck KGaA, EMD Serono

This study used real-world data to examine how often adverse events—specifically rash, peripheral neuropathy, and hyperglycemia—occur, how they are managed, and their impact on la/mUC treatment.

Concordance of response-based clinical trial and machine learning–generated real-world end points

Partner: Genentech

This study compared real-world data from the Flatiron Health Research Database to patients in the control arm of the IMpower132 clinical trial, and evaluated whether response-based outcomes could be reliably generated from routine clinical documentation using machine learning models.

Real-world progression-free survival of CDK4/6 inhibitors (CDK4/6i) plus an aromatase inhibitor (AI) in HR+/HER2− MBC in US routine clinical practice

Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer Center

This research used the Flatiron Health Panoramic database comprised of >740K patients with breast cancer to compare real-world progression free survival of nearly 10,000 patients treated with palbociclib, ribociclib, and abemaciclib in combination with an aromatase inhibitor.

Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse

Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer Center

This research used real-world data to highlight a significant gap in effective treatment options for adults and AYAs with B-ALL who relapse after two prior therapies.